Clinical trial · no report yet · Phase 1/Phase 2
PRIMAVERA
AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.
- NCT06137144 ↗
- Recruiting
- AstraZeneca
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| YouTube | 2 | |
| X threads | 1 |
The trial
ClinicalTrials.gov- Official title
- A Modular Phase I/II, Open-label, Multicentre Study to Evaluate the Safety, Tolerability, and Efficacy of AZD3470, a PRMT5 Inhibitor, as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies
- Phase
- Phase 1/Phase 2
- Status
- Recruiting
- Conditions
- Lymphoma; Non-Hodgkin Lymphoma; Hodgkin Lymphoma; Peripheral T-cell Lymphoma (PTCL); PTCL-NOS; ALCL; AITL
- Interventions
- AZD3470; Pembrolizumab
- Arms
- AZD3470 Monotherapy · Experimental
- AZD3470 in combination with Pembrolizumab · Experimental
- Enrollment
- 161 (estimated)
- Primary outcomes
- Incidence and severity of adverse events (AEs) and serious adverse events (SAEs)
- Incidence of DLTs (Dose Escalation Cohorts only)
- Sponsor
- AstraZeneca
- Start
- Jan 23, 2024
- Primary completion
- May 3, 2029 (estimated)
- Results posted
- No
- Registry record
- NCT06137144 · updated Oct 13, 2026